In ₹ Crore except Per Share 12 Months Ending | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Last 12M 30/06/2026 | |
|---|---|---|---|---|---|
| Adjustments to Reconcile Profit — Non-cash Items | |||||
| + Depreciation & Amortisation | 357.2 | 397.8 | 418.1 | — | |
| + Impairment Loss / (Reversal) | 11.1 | 0.0 | 0.0 | — | |
| + Finance Costs | 138.3 | 84.9 | 75.9 | — | |
| + Interest Income | -62.9 | -35.1 | -31.7 | — | |
| + Fair Value (Gains) / Losses | -7.2 | 5.7 | -0.0 | — | |
| + Share-based Payments | 3.1 | 2.1 | 0.8 | — | |
| + Unrealised FX (Gain) / Loss | -7.2 | 10.2 | 48.8 | — | |
| + Other Non-cash Items | -3.7 | 265.1 | 46.0 | — | |
| + Other — Cash Effects are Investing / Financing | -64.4 | -2.8 | -280.6 | — | |
| Changes in Working Capital | |||||
| + Inventories | -94.7 | -91.6 | -170.6 | — | |
| + Trade Receivables — Current | -75.8 | -217.7 | -48.9 | — | |
| + Other Financial Assets — Current | 8.5 | 36.4 | 2.6 | — | |
| + Other Financial Assets — Non-current | -11.6 | -3.7 | -3.0 | — | |
| + Other Current Assets | -59.6 | 92.4 | -11.2 | — | |
| + Other Non-current Assets | 47.7 | -8.7 | -49.1 | — | |
| + Trade Payables — Current | 21.5 | 72.7 | 66.8 | — | |
| + Other Financial Liabilities — Current | 85.3 | -42.9 | 45.6 | — | |
| + Other Current Liabilities | -3.1 | -35.5 | 2.5 | — | |
| + Other Non-current Liabilities | -0.7 | -0.4 | -0.2 | — | |
| + Provisions — Current | 224.8 | 12.9 | -130.0 | — | |
| + Provisions — Non-current | -108.3 | 9.5 | 1.6 | — | |
| Cash from Operating Activities | |||||
| Profit Before Tax (per I/S) | 842.7 | 1,131.1 | 1,572.5 | 1,814.1 | |
| + Total Adjustments (incl. Working Capital) | 398.3 | 551.4 | -16.6 | — | |
| Cash from Operations (pre-tax) | 1,241.0 | 1,682.6 | 1,555.9 | — | |
| + Income Taxes Paid | 296.3 | 361.3 | 414.0 | — | |
| Cash from Operating Activities | 944.7 | 1,321.3 | 1,142.0 | — | |
| Cash from Investing Activities | |||||
| + Acq of Fixed Assets (Capex) | 411.3 | 775.5 | 652.3 | — | |
| + Disp of Fixed Assets | 8.6 | 5.3 | -3.7 | — | |
| + Acq of Biological Assets | 0.0 | 0.1 | 0.0 | — | |
| + Disp of Other Long-term Assets | 0.0 | 0.0 | 339.0 | — | |
| + Sale of Investments (Equity / Debt) | 64.8 | 0.0 | 0.0 | — | |
| + Acq of Interests in Joint Ventures | 25.1 | 27.2 | 0.0 | — | |
| + Acq of Subsidiaries / Businesses (net) | 1,542.9 | 0.0 | 0.0 | — | |
| + Disp of Subsidiaries / Businesses (net) | 0.0 | 0.0 | 3.5 | — | |
| + Investment in Partnership Firms / LLPs | 0.0 | 6.3 | 0.0 | — | |
| + Loans & Advances Made | -21.2 | 24.8 | 27.9 | — | |
| + Loans & Advances Repaid | 2.0 | 32.1 | 11.3 | — | |
| + Interest Received — Investing | 80.9 | 24.0 | 31.5 | — | |
| + Other Inflows / (Outflows) — Investing | 510.0 | -97.1 | 51.8 | — | |
| Cash from Investing Activities | -1,291.8 | -869.5 | -246.8 | — | |
| Cash from Financing Activities | |||||
| + Proceeds from Borrowings | -180.1 | 218.4 | -77.8 | — | |
| + Repayment of Borrowings | 176.8 | 311.6 | 525.2 | — | |
| + Payment of Lease Liabilities | 10.7 | 18.0 | 22.4 | — | |
| + Payment of Finance Lease Liabilities | 2.5 | — | — | — | |
| + Interest Paid | 131.7 | 70.2 | 75.7 | — | |
| + Dividends Paid | 50.7 | 101.5 | 52.4 | — | |
| Cash from Financing Activities | -552.6 | -283.0 | -753.5 | — | |
| Net Changes in Cash (pre-FX) | -899.7 | 168.8 | 141.7 | — | |
| Net Changes in Cash | -899.7 | 168.8 | 141.7 | — | |
| Closing Cash | 755.8 | — | — | — | |
| Reference Items | |||||
| EBITDA | 1,321.2 | 1,726.1 | 1,978.6 | 2,231.7 | |
| EBITDA Margin % | 17.15 | 19.31 | 20.51 | 22.04 | |
| Free Cash Flow (CFO − Capex) | 533.4 | 545.8 | 489.7 | 489.7 | |
| Free Cash Flow to Equity | — | 389.8 | -183.8 | — | |
| Free Cash Flow per Basic Share | 21.02 | 21.51 | 19.30 | 19.30 | |
| Price to Free Cash Flow | — | — | — | 102.17 | |
| Cash Flow to Net Income | 1.81 | 1.68 | 0.96 | — | |
| Cash Paid for Taxes | 296.3 | 361.3 | 414.0 | — | |
| Cash Paid for Interest | 131.7 | 70.2 | 75.7 | — | |